Early clinical investigations employing IL-2 as an adjuvant for CAR T cell therapy in non-Hodgkin lymphoma demonstrated an increase in the frequency of FOXP3+ Treg cells (185, 186). Here, IL2 is linked to non-Hodgkin lymphoma.